Centanafadine

Centanafadine
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name (1R,5S)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane;
CAS Number	924012-43-1;
PubChem CID	16095349;
ChemSpider	17253639;
KEGG	D10697 ;
Chemical and physical data
Formula	C15H15N
Molar mass	209.28 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4;
	InChI InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1; Key:HKHCSWPSUSWGLI-CABCVRRESA-N;

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively.[1][2][3][4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.[5][6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.[7] As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.[8]

Centanafadine [1]
Site	IC₅₀ (nM)	Action	Ref
SERT	83 nM	Blocker	[1]
NET	6 nM	Blocker	[1]
DAT	38 nM	Blocker	[1]

References

"Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial" (PDF). Neurovance. Retrieved 14 January 2018.
"3-Neurotransmitters, 1-Molecule: Optimized Ratios". Neurovance.
"EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD" (PDF). Neurovance.
Frank P. Bymaster; Krystyna Golembiowska; Magdalena Kowalska; Yong Kee Choi; Frank I. Tarazi (June 2012). "Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder". Synapse. 66 (6): 522–532. doi:10.1002/syn.21538. PMID 22298359.
"Euthymics". Ethismos Research Inc. Retrieved 14 January 2018.
"EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD" (PDF). Neurovance. December 7, 2011. Retrieved 14 January 2018.
"Otsuka Pharmaceutical to Acquire Neurovance, Inc". Otsuka. Retrieved 14 January 2018.
"Otsuka U.S. Research & Development Programs". Otsuka U.S. Otsuka. Retrieved 14 January 2018.

External links

Centanafadine - AdisInsight

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[nM-1] "Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial" (PDF). Neurovance. Retrieved 14 January 2018.

[2] "3-Neurotransmitters, 1-Molecule: Optimized Ratios". Neurovance.

[3] "EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD" (PDF). Neurovance.

[4] Frank P. Bymaster; Krystyna Golembiowska; Magdalena Kowalska; Yong Kee Choi; Frank I. Tarazi (June 2012). "Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder". Synapse. 66 (6): 522–532. doi:10.1002/syn.21538. PMID 22298359.

[euthymics-5] "Euthymics". Ethismos Research Inc. Retrieved 14 January 2018.

[6] "EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD" (PDF). Neurovance. December 7, 2011. Retrieved 14 January 2018.

[7] "Otsuka Pharmaceutical to Acquire Neurovance, Inc". Otsuka. Retrieved 14 January 2018.

[Otsuka-8] "Otsuka U.S. Research & Development Programs". Otsuka U.S. Otsuka. Retrieved 14 January 2018.

Centanafadine

See also

References

External links